Nanobiotix S.A. NBTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.56% | 875.50% | 360.45% | 57.17% | -79.54% |
| Total Other Revenue | 12.34% | -11.25% | -30.58% | -41.63% | -49.48% |
| Total Revenue | 18.89% | 2,058.32% | 562.47% | 27.44% | -75.28% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 18.89% | 2,058.32% | 562.47% | 27.44% | -75.28% |
| SG&A Expenses | 1.13% | 4.49% | 3.25% | -0.98% | -3.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.46% | -20.80% | -26.08% | -21.26% | -15.77% |
| Operating Income | 27.33% | 60.99% | 82.73% | 39.69% | -96.58% |
| Income Before Tax | -10.08% | 30.74% | 62.57% | 24.85% | -55.94% |
| Income Tax Expenses | 138.10% | -72.81% | -97.16% | -109.28% | -114.13% |
| Earnings from Continuing Operations | -10.18% | 30.76% | 62.62% | 25.15% | -54.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.18% | 30.76% | 62.62% | 25.15% | -54.61% |
| EBIT | 27.33% | 60.99% | 82.73% | 39.69% | -96.58% |
| EBITDA | 26.34% | 61.45% | 83.84% | 39.55% | -108.22% |
| EPS Basic | -7.37% | 32.35% | 63.19% | 27.49% | -43.07% |
| Normalized Basic EPS | 0.24% | 37.00% | 65.25% | 23.99% | -79.12% |
| EPS Diluted | -7.35% | 32.28% | 63.08% | 27.55% | -42.18% |
| Normalized Diluted EPS | 0.24% | 37.00% | 65.25% | 23.99% | -79.12% |
| Average Basic Shares Outstanding | 2.40% | 1.79% | 1.17% | 5.54% | 10.33% |
| Average Diluted Shares Outstanding | 2.40% | 1.79% | 1.17% | 5.54% | 10.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |